Mechanism of Action
Pulsatile vs Continuous Signaling
GnRH receptors on pituitary gonadotrophs respond differentially to pulsatile vs continuous stimulation. Pulsatile GnRH (every 60-120 min, mimicking hypothalamic pulse generator) maintains receptor sensitivity and drives LH and FSH secretion. Continuous GnRH causes receptor downregulation and gonadotropin suppression within 7-14 days, the pharmacological basis of GnRH agonist analogs (leuprolide, nafarelin) used for castration in hormone-sensitive cancers.
Downstream Gonadotropin Effects
LH stimulates Leydig cell testosterone production (males) and triggers ovulation via LH surge (females). FSH stimulates spermatogenesis (males) and follicular development/estrogen production (females). Pulsatile gonadorelin therapy fully recapitulates normal HPG axis function, enabling spermatogenesis and fertility in hypogonadotropic hypogonadism where endogenous GnRH pulses are absent.
Research Summary
Hypothalamic Amenorrhea
FDA ApprovedPulsatile gonadorelin pump therapy restores ovulatory cycles in 80-90% of hypothalamic amenorrhea patients (Kallmann syndrome, functional hypothalamic amenorrhea). Multiple case series and uncontrolled studies demonstrate pregnancy rates of 80-90% over multiple treatment cycles, comparable to gonadotropin injections but with more physiological FSH/LH ratio and lower multiple pregnancy risk.
Male Hypogonadotropic Hypogonadism
Well EstablishedPulsatile gonadorelin restores testicular function in men with hypothalamic hypogonadism, including testosterone production and spermatogenesis. Treatment normalizes testicular volume and achieves sperm in ejaculate in 70-80% of patients. Compared to hCG/FSH combination therapy, gonadorelin provides more physiological stimulation and may better preserve gonadotropin feedback.
Diagnostic Testing
FDA ApprovedSingle 100 mcg IV/SC gonadorelin dose used as GnRH stimulation test to assess pituitary reserve. Normal LH response (3-fold or greater rise at 30-60 min) distinguishes pituitary from hypothalamic causes of hypogonadism. Used in evaluation of delayed puberty, hypogonadism workup, and monitoring recovery of HPG axis after suppression.
Calculate your Gonadorelin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Diagnostic GnRH stimulation test | 100 mcg IV or SC bolus; measure LH/FSH at 0, 30, 60 min | Single dose | Intravenous or subcutaneous |
| Hypothalamic amenorrhea (pulsatile) | 2.5-20 mcg/pulse via pump every 90 minutes | Continuous pulsatile | Subcutaneous or IV pump |
| Male hypogonadotropic hypogonadism | 5-20 mcg/pulse every 90-120 minutes | Continuous pulsatile | Subcutaneous pump |
Pulsatile pump therapy requires specialized equipment. Dose titrated to normalize testosterone/LH levels. Monitor ovarian ultrasound in female patients to prevent hyperstimulation.
Interactions
Safety Profile
Gonadorelin is generally well tolerated at therapeutic doses. Injection site reactions (pain, swelling) are the most common adverse effects with pump therapy. Headache, nausea, and lightheadedness may occur after bolus doses. Female patients on pulsatile therapy: ovarian hyperstimulation syndrome risk is low (unlike gonadotropin therapy) but ovarian ultrasound monitoring is still recommended. Multiple pregnancies possible. Male patients: gynecomastia occasionally with supraphysiological stimulation. Anaphylaxis is rare but possible; patients should be observed after first dose.
References
- [1]Leyendecker G, et al. Induction of ovulation with chronic intermittent (pulsatile) administration of GnRH in women with hypothalamic and hyperprolactinemic amenorrhea. Arch Gynecol. 1980;229(3):177-190.
- [2]Whitcomb RW, Crowley WF Jr. Diagnosis and treatment of isolated gonadotropin-releasing hormone deficiency in men. J Clin Endocrinol Metab. 1990;70(1):3-7.